**Carboplatin**

**Section:** 8. Immunomodulators and antineoplastics ➔ 8.2. Antineoplastics and supportive medicines ➔ 8.2.1. Cytotoxic medicines

### Summary of evidence and Expert Committee recommendations

Carboplatin was originally added to the complementary list of the EML in 2009 as a treatment of advanced ovarian cancer. In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for carboplatin on the complementary list of the EML for use in treatment protocols for non-small cell lung cancer was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee’s consideration of treatment protocols for non-small cell lung cancer is attached.

### Essential medicine status

- **ATC codes:** L01XA02
- **ICD11 code:** 2C75.Y

### Indication

Other specified malignant neoplasms of bronchus or lung

### INN

Carboplatin

### Medicine type

Chemical agent

### List type

Complementary

### Formulations

Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

### EML status history

First added in 2009 (TRS 958)

Changed in 2015 (TRS 994)

### Sex

All

### Age

Adolescents and adults

### Therapeutic alternatives

The recommendation is for this specific medicine

### Patent information

Patents have expired in most jurisdictions

Read more about patents.

### Tags

- Cancer

### Wikipedia

- Carboplatin

### DrugBank

- Carboplatin